155219-34-4

Upstream product

• 147611-86-7 rac-3,4-dihydro-7-hydroxy-8-propyl-2H-1-benzopyran-2-carboxylic acid ethyl ester 
• 4460-42-8 1-(5-ethyl-2,4-dihydroxyphenyl)ethanone 
• 155219-33-3 7-<(3-chloropropyl)oxy>-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid ethyl ester 
• 42368-92-3 7-hydroxy-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid ethyl ester 

Downstream Products

• 156005-67-3 7-{3-[4-((Z)-3-Dimethylamino-acryloyl)-2-ethyl-5-hydroxy-phenoxy]-propoxy}-8-propyl-chroman-2-carboxylic acid ethyl ester 
• 156005-50-4 7-[3-(4-acetyl-2-ethyl-5-hydroxyphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid 
• 156005-28-6 3,4-dihydro-8-propyl-7-<<3-<2-ethyl-5-hydroxy-4-<3-(dimethylamino)-1-oxo-2-propenyl>phenoxy>propyl>oxy>-2H-1-benzopyran-2-carboxylic acid 

Relevant academic research and scientific papers

USE OF PLA2 INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE

This invention provides methods for the treatment or prevention of Alzheimer's disease in a mammal which comprises administering to a mammal in need thereof an effective amount of an inhibitor of phospholipase A2. This invention also provides a series of compounds which are useful as inhibitors of phospholipases A2, especially cytosolic phospholipase A2.

LEUKOTRIENE B4 ANTAGONISTS

This invention provides certain 1,2,4,5 substituted benzene derivatives containing "acid" substituents derived from cyclic or heterocyclic moieties. These unique compounds are leukotriene B 4 antagonists and formulations of these derivatives, and a method of using these derivatives for the treatment of conditions characterized by an excessive release of leukotrienes. "

Leukotriene B4 (LTB4) receptor antagonists: a series of (hydroxyphenyl)pyrazoles.

A series of (hydroxyphenyl)pyrazoles was designed by molecular modeling comparison with the LTB4 structure and prepared for evaluation as LTB4 receptor antagonists, culminating in 4-ethyl-5-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]-2-(1H-pyrazol -3- yl)p